Development of chronotherapeutics in rheumatoid arthritis
Not Applicable
- Conditions
- rheumatoid arthritis
- Registration Number
- JPRN-UMIN000040094
- Lead Sponsor
- Department of Diabetes, Endocrinology and Clinical Immunology, School of Medicine, Hyogo Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
Not provided
Exclusion Criteria
1)chronic kidney (eGFR<50ml/min/1.73m2) 2)svere infection or tuberculosis 3)Neutrophils<500/ul, lymphocytes<500/ul 4)Pregnant woman 5)Complication of malignant tumor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Achievement rate of ACR20 at week 12
- Secondary Outcome Measures
Name Time Method 1) change of DAS28ESR and CDAI (week 4, 8, 12, 24, 52) 2) the remission rate of DAS28ESR and CDAI (week 12) 3)Achievement rate ofACR20 (week 4, 8, 24, 52), 50, 70 (week 4, 8, 12, 24, 52) 4) Biomarker (CRP, ESR, MMp-3, RF) 5)change of ACR core set (week 4, 8, 12, 24, 52) 6) Radiograghic X ray